ABSTRACT
Aims To evaluate whether adding financial incentives to usual care is cost-effective in encouraging pregnant women to quit tobacco smoking, compared to usual care alone.
Design Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) from a healthcare provider’s perspective, embedded in the Smoking Cessation in Pregnancy Incentives Trial (CPIT III). Long-term analyses were conducted from the same perspective, using an existing Markov model over a lifetime horizon.
Setting Seven maternity smoking cessation sites in Scotland, England and Northern Ireland in the United Kingdom.
Participants In the short-term analysis CPIT III participants were assessed: women 16 years or older, self-reporting as smokers, less than 24 weeks pregnant and English speaking (n=944). The same population was used for the lifetime analysis, plus their infants.
Measurements Costs include financial incentive vouchers and postage, cessation support and nicotine replacement therapy and neonatal stays. The outcome measure was biochemically verified quit rate for the CEA and quality adjusted life-years (QALY) for CUA. Costs are presented in 2020 GBP sterling (£).
Data for the lifetime analysis came from the trial and was combined with data from published literature embedded in the model, reporting incremental cost per quitter and QALY. A 3.5% discount rate was applied.
Findings The short-term incremental cost per quitter was £4,400, uncertainty in QALY gains resulted in a cost per QALY of £150,000. Results of sensitivity analyses confirm these results. The long-term analysis combined costs and outcomes for mother and infants, results show a cost saving of £37 (-£35 to £106) and increase in QALYs of 0.171 (0.124 to 0.229). These findings indicate that, over a lifetime, financial incentives are cost saving and improve health outcomes.
Conclusions Offering up to £400 financial incentives, in addition to usual care, to support pregnant women to stop smoking is cost-effective over a lifetime for mother and infants.
Ethics Ethics approval received from NHS West of Scotland Research Ethics Committee-2, August 2017.
Registration details Trial registration number: ISRCTN15236311, date registered 09/10/2017 https://doi.org/10.1186/ISRCTN15236311
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN15236311
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/33109658/
Funding Statement
Cancer Research UK (C48006/A20863), Chief Scientist Office Scottish Government (HIPS/16/1), Health and Social Care Services Northern Ireland (COM/5352/17), Chest Heart & Stroke Northern Ireland (2019_09), Lullaby Trust (272), Scottish Cot Death Trust (no reference available), Public Health Agency NI (no reference available).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS West of Scotland Research Ethics Committee-2 gave ethical approval for this work in August 2017.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Trial registration Current Controlled Trials ISRCTN15236311 date registered 09/10/2017 https://doi.org/10.1186/ISRCTN15236311
Declaration of competing interest Nicola Mcmeekin: I declare grant funding from Chief Scientists Office and Cancer Research UK for the CPIT III project (research time).
Lesley Sinclair: I declare grant funding from Cancer Research UK for the CPIT III project (named researcher).
Lyn Robinson-Smith: I declare no conflicts of interest.
Alex Mitchell: I declare no conflicts of interest.
Linda Bauld: I declare grant funding from Chief Scientists Office for the CPIT III project (research time). I am also co-chair of the Smoking in Pregnancy Challenge Group (England) and (since Sept 2021) Chief Social Policy Adviser to the Scottish Government.
David Tappin: I declare grant funding from Chief Scientists Office and Cancer Research UK for the CPIT III project.
Kathleen A Boyd: I declare grant funding from Chief Scientists Office and Cancer Research UK for the CPIT III project (funding research time).
lesley.sinclair{at}york.ac.uk
lyn.robinson-smith{at}york.ac.uk
alex.mitchell{at}york.ac.uk
linda.bauld{at}ed.ac.uk
david.tappin{at}glasgow.ac.uk
kathleen.boyd{at}glasgow.ac.uk
Data Availability
All requests for data should be submitted to NM (nicola.mcmeekin{at}glasgow.ac.uk) for consideration. Access to anonymised data may be granted following review by the Trial Management Group and agreement of NM and DT. The data are not publicly available due to privacy or ethical restrictions.
